Metabolic complications associated with antiretroviral therapy.
about
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionEffect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trialHigh frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virusAccess to antiretroviral therapy for adults and children with HIV infection in developing countries: Horizons studies, 2002-2008Impacts of highly active antiretroviral therapy (HAART) on metabolic status of patients with AIDS: What happens from the initiation of AIDS to the initiation of treatment?Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation.Mid-ATR-FTIR spectroscopic profiling of HIV/AIDS sera for novel systems diagnostics in global health.Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African womenEffects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal womenLongitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruptionHIV status and the risk of ischemic stroke among men.The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs.Structured treatment interruptions in HIV infection: benefit or disappointment?Treatment of HIV infection in the older patient.Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Adiposity influences airway wall thickness and the asthma phenotype of HIV-associated obstructive lung disease: a cross-sectional studyAnti-retroviral therapy induced diabetes in a Nigerian.ORTHOPEDIC COMPLICATIONS IN HIV PATIENTS.Metabonomic analysis of HIV-infected biofluids.Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy.Ischaemic stroke in HIV-infected patients: a case-control study.Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase.A combined chemometric and quantitative NMR analysis of HIV/AIDS serum discloses metabolic alterations associated with disease status.Predictive models for maximum recommended therapeutic dose of antiretroviral drugs.Select HIV protease inhibitors alter bone and fat metabolism ex vivo.Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta).Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening.Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population.Effect of Lipodystrophy on the Quality of Life among People Living with HIV (PLHIV) on Highly Active Antiretroviral Therapy.[Evaluation of the polymorphisms in methylenetetrahydrofolate reductase gene and the levels of folate and B12 in HIV-infected patients under antiretroviral therapy].Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort.Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation.Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study.Inhibitors of HIV-1 protease: 10 years after
P2860
Q24536249-959BF094-6166-4420-91BB-22288EA63870Q24645513-1CD8BF95-9680-46F2-8126-6B4176AED7F1Q24814179-14DBB648-50AE-43C9-BED9-A098C337A1DAQ33652805-6C2C476E-86EA-4C94-9F02-9E6EE4CA9494Q33771382-C0193B7F-DCDD-43EB-9054-A968A9869DF8Q33787957-A5D746BE-1FF5-48A1-8786-9D930950B21CQ33942033-50404407-E8AB-4ABB-9FD4-9C277DBE0E43Q34138834-2F2314DC-F0E4-484F-B185-FA0B06C0ECB2Q35055196-C82F6001-04EF-46A6-BAF4-439B51064CEFQ35205571-77B8154B-BF21-428E-8CCA-E9AA8AB89AD6Q35611619-69285243-6384-4FCA-9340-F55423E59FAFQ35740281-560BCE35-3D68-4705-AFEB-40712E6810BBQ35917152-B520EBB2-ED73-429E-98D9-C340A14CAE5BQ35917538-3B81D75B-C05A-4B1C-89CC-72C7E3FB5FB0Q36011828-3D9BB85D-E52E-4926-B20E-1268BA657ACCQ36094376-5448C56D-617F-46DB-9B56-D491CF008123Q36500756-89A930E3-19DB-41AB-81F3-32D4C1705846Q36666462-974B04F0-B155-45C7-BCA8-557156F69629Q38056813-8A6CB5E7-C539-4952-A851-E8D12F42E025Q39912333-33C49398-952E-47E6-BF52-C609010E951BQ40572144-F1BDFC41-427A-4DC5-83F7-AF2C563C9E71Q40594909-8C5C5922-E7F2-46EE-BB38-939761B34D1EQ40763708-06A0899C-A352-47CB-9359-EA71A1EA3D81Q41352945-8720D312-021C-46B6-A1F5-8259DEAE5871Q42589175-2BB87A8E-CC2D-4EF3-94EE-C46546C2D200Q43950615-50372500-27D5-4A27-A2EC-54FA584CAE71Q44242461-A1136F06-9036-439A-9303-30DAC2F857FCQ44540998-54597EB4-A2C5-4CF3-874C-AEF7BF46536EQ44794028-5FB7CEAE-07F7-47F8-8908-FEEBE23B7FE9Q45041241-71AE7295-8FA7-41B4-8D6D-CE9ADFAF38EDQ46376382-BB17E109-D441-4721-98BD-BC596A47D359Q46880626-3BB988FB-6F5C-459B-A8DB-6E363E5E96F6Q47204696-A75B33AB-A1B3-4262-BE10-DF750467DA85Q51299240-22551E48-41FE-4411-B0CE-4086EC3DAE12Q58389026-A78B40C1-60B1-4463-80AE-76EC94DF51B4
P2860
Metabolic complications associated with antiretroviral therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Metabolic complications associated with antiretroviral therapy.
@ast
Metabolic complications associated with antiretroviral therapy.
@en
Metabolic complications associated with antiretroviral therapy.
@nl
type
label
Metabolic complications associated with antiretroviral therapy.
@ast
Metabolic complications associated with antiretroviral therapy.
@en
Metabolic complications associated with antiretroviral therapy.
@nl
prefLabel
Metabolic complications associated with antiretroviral therapy.
@ast
Metabolic complications associated with antiretroviral therapy.
@en
Metabolic complications associated with antiretroviral therapy.
@nl
P2093
P1433
P1476
Metabolic complications associated with antiretroviral therapy.
@en
P2093
P304
P356
10.1016/S0166-3542(01)00148-6
P577
2001-09-01T00:00:00Z